logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Trick or Trade

Sorrento Therapeutics Releases Preclinical Data from STI-1499 and STI-2020 Demonstrating Potent Neutralizing Antibodies Against SARS-CoV-2

Sorrento Therapeutics Preclinical Data of Neutralizing Antibodies Against SARS-CoV-2 In preclinical studies, both STI-1499 and STI-2020 demonstrated potent neutralizing activity against SARS-CoV-2 virus isolates, including the emerging Spike D614G variant virus. Both STI-1499 and STI-2020 demonstrated protective activities against SARS-CoV-2...

Read More

September 29, 2020

0

Our Plan as the Stock Market Continues to Plummet

The Stock Market Continues to Plummet Indeed, the Stock Market continues to decline, losing investors' profits.   Each time the Market plummets it takes with it promising firms' stocks but when the biotech stocks plummet new reasons are always claimed...

Read More

February 17, 2022

0

The Time Has Come to Present Mirum Pharmaceuticals Inc

Mirum Pharmaceuticals Inc Mirum Pharmaceuticals Inc ( MIRM ) is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Maralixibat, is Mirum Pharmaceuticals lead product candidate. The product...

Read More

September 27, 2021

0

SARS-CoV-2 Virus vs The President of the United States

President Trump, the First Lady and COVID-19 Indeed, the complicated, nasty SARS-CoV-2 virus managed to infect President Trump and the First Lady when we were expecting a vaccine to soon be ready to protect the country and the world from...

Read More

October 5, 2020

0

Our Most Pressing Need. See Also: Important, Recent News from Incyte & Eli Lilly and Halozyme

Our Most Pressing Need Our current, most pressing need is news that makes sense. Stock Market investors are waiting for comprehensive news regarding inflation in the U.S., the rest of the world's economy and the price of crude oil. Indeed,...

Read More

March 29, 2022

0

What's Going on with the Clinical-Stage Biotech Firms. See Also: Promising News From Evotec SE

The Clinical Stage Biotech Firms   We have reasons to believe that some clinical-stage biotechnology firms, which have yet to generate revenues, have solid scientific fundamentals, breakthrough technologies and extremely promising  products that will generate billions of dollars in future...

Read More

April 9, 2022

0

Agenus Strategic Decision to Withdraw the BLA for Balsitilimab

Agenus to Withdraw BLA for Balstilimab Agenus ( AGEN ) announced a strategic decision to withdraw its Biologics License Application ( BLA ) for balstilimab, its PD-1 inhibitor. The firm stated that its decision will not change the development plans...

Read More

October 22, 2021

0

Kite Pharma’s Yescarta® Approved by the EC for Adults with Relapsed or Refractory Follicular Lymphoma

Kite Pharma - A Gilead Company In The NEWS Gilead Sciences' ( GILD ) firm Kite Pharma, announced that the European Commission ( EC ) has approved its CAR T-cell therapy Yescarta® (axicabtagene ciloleucel) for adult patients with relapsed or refractory...

Read More

June 29, 2022

0

Acquired by Merck or Not, Seagen Will, Sooner or Later, Outperform

Is Merck to Acquire Seagen? The Wall Street Journal reported that Merck is in advanced talks to buy Seagen in a deal that could be worth $40 billion or more. The report, cited by people familiar with the matter, said...

Read More

July 8, 2022

0

A New COVID-19 Vaccine is Showing Successful Results. See Also: More Details About the Effective COVID-19 Vaccines

COVID-19 Vaccine Updates Pfizer's ( PFE ) /BioNTech's ( BNTX ) and Moderna's ( MRNA ) COVID-19 vaccines have demonstrated safety at around 95% efficacy.   AstraZeneca ( AZN ) and Oxford University announced today that their COVID-19 vaccine was...

Read More

November 23, 2020

0

  • Previous
  • 1
  • 2
  • ...
  • 7
  • 8
  • 9
  • ...
  • 16
  • 17
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy